12 Global Ophthalmology Innovation Awards 2026 Announced at Beijing Summit
Century Healthcare
Medical Device Manufacturer, R&D, and Distributor
On June 11, 2026, the Second Global Ophthalmology Conference was held at the Conference Center of the Zhongguancun Exhibition Center in Beijing.
AsSiYu MedTech Annual Medical Technology Series Conferencean important component of,This conference has attracted participants from hospitals, research institutes, innovative enterprises, investment institutions, and industrial service platforms.More than 600Professional guests attended for on-site exchanges.The ophthalmology conference focuses on innovative ophthalmic devices, intraocular lenses, ophthalmic imaging, myopia prevention and control, digitalization in ophthalmology, neuro-ophthalmology, and innovations in clinical applications. It brings together representatives from both the industry and clinical sectors to jointly discuss the latest advancements and implementation pathways for technological innovation in ophthalmic healthcare.
At the conference venue,2026Global Ophthalmology Innovation Awards SeriesAnnounced. This year's awards feature two categories: the Ophthalmic Innovative Device Award and the Ophthalmic Application Innovation Award.Among these, the Ophthalmic Innovative Device Award primarily focuses on representative enterprises that have obtained approval for innovative product registration applications from the National Medical Products Administration (NMPA), entered the special review procedure for innovative medical devices, or achieved breakthroughs in key ophthalmic technology areas. The Ophthalmic Application Innovation Award, on the other hand, emphasizes the application value of ophthalmic products, technologies, and services in clinical diagnosis and treatment, screening and prevention, digital management, and healthcare service systems.
Note: Siyu organizes award evaluations twice a year, and the jury can only select from the registered units. Therefore, please pay attention to the notifications and actively apply.
The list of award winners is as follows (in no particular order).
Reason for Award:
Hangzhou Nuanxinjia Electronic Technology Co., Ltd., established in 2014, has long been dedicated to the research and development of cutting-edge technologies such as brain-computer interfaces and biochips, forming relatively comprehensive technical capabilities in chip design, packaging, implantable components, and medical terminals.
The company’s visual brain-computer interface products are designed to meet the needs of visually impaired patients, including those who are completely blind or have lost their field of vision. Multiple animal experiments have been completed, and the products have passed medical device type testing., atRecently, the first GCP clinical trial of a visual brain-computer interface was completed in China, and the patient was able to clearly recognize letters on the second day after the device was powered on.This is the fastest recorded recovery of visual perception reported publicly to date.，It fully demonstrates China's domestic innovation strength and advanced progress in the field of visual reconstruction.
Visual brain-computer interfaces represent a critical interdisciplinary frontier integrating ophthalmology, neuroscience, chip engineering, and neuromodulation. Nuanxinjia Technology has continuously tackled key challenges, including high-resolution electrical stimulation, implant miniaturization, hermetic sealing, dynamic parameter modulation, and charge balancing. This effort provides a representative case for the transition of domestic invasive visual brain-computer interface products from research and development validation to clinical translation.
Reason for Award:
Tianjin Century Healthcare Biomedical Engineering Co., Ltd. is an ophthalmic medical device enterprise integrating R&D, production, and sales. The company has long focused on the development of intraocular lenses and visual optics products, establishing a comprehensive product portfolio that covers hydrophilic, hydrophobic, monofocal, and multifocal categories.
The company’s Liang Shi An® Trifocal Plus intraocular lens was approved for market launch by the National Medical Products Administration in 2025 and is classified as an innovative medical device.This product, designed to meet the full-spectrum vision needs throughout the post-cataract surgery period, adoptsTargetedRelated to Light Field DistributionPatentDesign, optimized for continuity across distance, intermediate, and near vision ranges and for luminous energy utilization efficiency, this product is alsoNMED (National Innovation Center for High-Performance Medical Devices)”2025 Innovative Medical Device Product Rising Star"the only ophthalmic product in。CompanyAnother ModelInnovative Medical DevicesWan Shi An® Ultra-EDoF extended depth-of-focus intraocular lens was also approved for market launch in 2025, further enriching the selection of domestically produced high-end functional intraocular lenses.。
As one of the few companies in China with multiple approved innovative intraocular lens (IOL) products, Century Healthcare has established a systematic technological layout in the field of high-end domestically produced IOLs, providing more Chinese-made options for improving postoperative visual quality in cataract patients.
Reason for Award:
Suzhou Bigway Medical Technology Co., Ltd. specializes in the research and development of software and hardware systems for AI-based analysis and diagnosis in ophthalmic imaging. The company has established a product portfolio centered on multimodal AI analysis and diagnostic software for fundus imaging, complemented by intelligent hardware such as Optical Coherence Tomography (OCT) devices, ultra-widefield fundus cameras, and dry eye detectors. By leveraging cutting-edge technology to enhance ophthalmic diagnosis and treatment, Suzhou Bigway is committed to building a globally leading brand in ophthalmic artificial intelligence.
The company's ophthalmic OCT image-assisted diagnostic software, MIAS-3000, obtained the Class III medical device registration certificate in 2025.This software is designed for the assisted diagnosis of fundus diseases using OCT images. Validated through multi-center clinical trials, it aids physicians in disease identification and staging assessment, and has been recognized as a winning entity in the Ministry of Industry and Information Technology’s Artificial Intelligence Medical Device Innovation Task Force.
The Clinical Value of AI in Ophthalmology: Key to Successful Integration into Diagnostic and Treatment Workflows, Enhancing Screening Efficiency, Reducing the Risk of Missed or Misdiagnoses, and Supporting Primary Healthcare Institutions. The Approval and Implementation of Bigwei MIAS-3000 Provides a Representative Case for the Transition of Ophthalmic Imaging AI from Algorithm Research to Compliant Clinical Application.
Reason for Award:
Intalight Saiwei has long been dedicated to the research, development, and manufacturing of high-end ophthalmic diagnostic and therapeutic equipment. Focusing on ultra-widefield imaging, swept-source technology, femtosecond lasers, and artificial intelligence, the company has established the "Ruyi" series matrix of ophthalmic diagnostic products.
In 2026, the company globally launched the “Ruyi 600,” a commercial swept-source OCT system with 600,000 A-scans per second, and the “Ruyi Center,” a dual ultra-widefield split multimodal imaging platform.Among them, Ruyi 600New ProductComplete a 150° ultra-widefield OCTA scan in just 5 seconds, achieving ultra-high-speed, precise imaging. As the connectivity hub for the Ruyi series, Ruyi Center enables cross-product multimodal integration and digital connectivity, transitioning from rapid acquisition to multimodal synergy and ushering in a new workflow for fundus imaging.。
The company’s core product, Ruyi Whole-Eye OCT, focuses on whole-eye imaging and ultra-widefield OCTA applications, further expanding the boundaries of ophthalmic imaging diagnosis. It has now been installed in overQianRuyi True Color Camera utilizes multi-source continuous spectrum true-color imaging technology, with a single imaging field of view reaching 186°, comprehensively enhancing the efficiency of diagnosis, teaching, and doctor-patient communication for fundus diseases. The Ruyi Full Cornea Biometer employs advanced swept-source technology, integrated with panoramic visualized fundus imaging mode and a proprietary telecentric optical system, featuring built-in advanced IOL calculation formulas to support preoperative cataract assessment and intraocular lens power calculation.
The award-winning value of Saiwei lies in its continuous innovation in optical systems, imaging platforms, and AI algorithms, which has enabled the construction of a comprehensive ophthalmic diagnostic equipment portfolio covering fundus, cornea, biometry, and OCT. Through innovative achievements such as the “Ruyi Center” and “Ruyi 600,” Saiwei is driving ophthalmic imaging toward ultra-widefield, ultra-high-speed, and intelligent capabilities, thereby providing more complete and efficient imaging and measurement tools for clinical ophthalmology.
Reason for Award:
Guangzhou Shijing Medical Software Co., Ltd.Established in 2008，is a leading domesticA comprehensive provider of visual health solutions, the company owns well-known brands such as “Beibele” and “Duobaoshi,” with business operations covering vision training, photobiomodulation (PBM), and myopia prevention and control. Committed to technological innovation and ecosystem co-creation, the company drives the transformation and upgrading of the optometry industry from traditional eyewear dispensing to professional eye health management.。
Companyunder the banner ofGuanglang BiotechTechnologyBeibeile PBM-LED Red Light Myopia Treatment Device, which obtained the Class II Medical Device Registration Certificate in 2025, the first medical device approved after the national new red light policy。This productwithQuadruple protection, 10-fold safety redundancy, far exceeding international authoritative safety standards;AdoptTen-Step Parameterized Optical Path Design for Efficient Axis and Degree Control; Clinical studies have confirmed that Beibeile can effectively delay axial elongation; Beibeile originates fromPhotobiomodulation Technology: A New Interventional Tool for Axial Length Control and Myopia Management in Adolescent Myopia Prevention and Control Scenarios
Myopia prevention and control have long been a key focus in ophthalmic public health and clinical services. Shijing Medical has established a continuous strategic layout centered on digital therapeutics, photobiological therapy, and an optometric management platform, driving the evolution of myopia prevention and control from standalone examination and eyewear dispensing services toward an integrated approach combining screening, intervention, follow-up, and digital management.
Reason for Award:
Anshikang Medical Technology, established in 2021, specializes in the research, development, manufacturing, and service of software and hardware products in the fields of ophthalmology and optometry, covering a wide range of eye health management scenarios including households, schools, communities, and medical institutions.Currently, the company has established three core product systems, including precision ophthalmic diagnosis and treatment solutions, optometry retail store solutions, and school-based screening solutions.
The company's ophthalmic optical biometer, "Swan," focuses on myopia management.and other scenariosto meet the requirements for axial length measurement, with innovations in multispectral low-reflection technology and peripheral axial length measurement.The product enhances examination efficiency and data consistency through multi-parameter parallel acquisition and low-reflection signal optimization; its peripheral fixation system guides off-axis gaze, enabling axial length measurements at multiple angles in the nasal-temporal and superior-inferior directions.
As myopia prevention and control enter a phase of refined management, single central axial length data can no longer meet the needs for personalized assessment. Anshikang provides new data dimensions for monitoring the onset and progression of myopia and evaluating personalized interventions by expanding parameters such as peripheral axial length.
Reason for Award:
As the first biomedical listed company in China with an “H+STAR Market” structure，Shanghai Haohai Biological Technology Co., Ltd. has long maintained a strategic presence in therapeutic areas including ophthalmology, medical aesthetics, orthopedics, and surgery.Haohai OphthalmologyDeep CultivationOphthalmologyFor 18 years, rooted in China with a global vision,Our business covers multiple areas, including cataracts, optometry, refractive surgery, ocular surface, and fundus.Subspecialty, formingA pipeline of end-user products covering the entire lifecycle of eye health.
Companyunder the banner ofQuanShiJia®It is the world’s first full-range-of-vision intraocular lens featuring five-level optical efficiency, designed based on the patented technology of Fourier harmonic penta-focal diffractive intraocular lenses. This product is based on the independently developed COMPLUSAGE®(Complete Light Usage) technology, through an innovative five-focus Fourier harmonic diffractive design, achieves nearly 100% light energy utilization efficiency under conditions where the pupil diameter is less than 3.5mm, constructing a more continuous and smooth visual transition between distance, intermediate, and near vision., effectively improving intermediate vision in trifocal lenses.It is worth noting that the companyAnother InnovationProduct EnjoymentBoundary®XiangPosition-optimized trifocal intraocular lens,With itsTechnical Innovation and Clinical Value,CompletedApproved for market launch via the National Special Approval Channel for Innovative Medical Devices, with its astigmatism-correcting version expected to receive approval and be launched within this year.
The award-winning value of Haohai Biological Technology lies in,WithIndependently DevelopedInnovative TechnologyBreaking Through the Technical Bottleneck of Traditional Multifocal Intraocular Lenses Designed Using Fresnel Principles，Not onlyProvides a domestically produced solution for cataract patients that combines excellent visual quality with clinical accessibility,furtherValidated the feasible pathway for breakthroughs in original technologies under the medical-engineering collaborative model. Meanwhile,，It provides robust empirical evidence for the leap of domestically produced high-end ophthalmic consumables from “following” to “leading,” driving the industry toward a new landscape defined by technology.
Reason for Award:
GaoShi Innovation Technology Co., Ltd. is GaoShi MedicalTechnologyThe Group’s active medical device R&D and manufacturing platform for ophthalmology, located in the Precision Medical Industrial Park in Xishan District, Wuxi, leverages the Group’s extensive expertise in the ophthalmic field to continuously advance the R&D and domestic production of high-end ophthalmic diagnostic equipment.
The company’s independently developed T3 series of corneal confocal microscopes achieves a technical balance between wide field of view and high resolution, addressing the need for in vivo cellular-level imaging of the cornea.This product utilizes a laser light source and tomographic confocal scanning technology to achieve high-resolution imaging over a large field of view, enabling the observation of cellular structures in all layers of the living cornea.
In clinical practice, corneal confocal microscopy provides imaging evidence for the diagnosis, follow-up, and pathological study of corneal and conjunctival diseases such as infectious keratitis, keratoconus, and dry eye.The launch of the GaoShi Innovation T3 series reflects the continuous breakthroughs of domestically produced ophthalmic diagnostic equipment in specialized clinical scenarios.
Reason for Award:
Shenzhen Feimou Medical Device Technology Co., Ltd. was established in 2022, focusing on the clinical translation of femtosecond lasers in ophthalmic surgery and primarily developing femtosecond laser treatment systems for ophthalmology.
The company focuses on the demand for domestic production of high-end refractive and corneal surgical equipment,Focus on Personalized SMILE High-Order Aberration Correction，Develop independent R&D of core components and complete systems for femtosecond lasers,Focus on tackling key technological challenges, including high-precision, wide-field 3D optical scanning systems, medical-grade femtosecond lasers, real-time closed-loop monitoring and control technologies, and customized refractive correction algorithms.In 2025, the mass-production prototype of Feimou Medical's ophthalmic femtosecond laser treatment system passed the national type testing and obtained the report.
Femtosecond laser treatment systems represent a key direction for high-end ophthalmic surgical equipment, demanding long-term expertise in optics, lasers, control algorithms, and system integration. The R&D progress of Feimou Medical provides a new industrial model for advancing domestically produced ophthalmic femtosecond laser devices into clinical translation and regulatory registration stages.
Reason for Award:
The team affiliated with the Eye, Ear, Nose, and Throat Hospital of Fudan University has long focused on the diagnosis and treatment of ectatic corneal diseases such as keratoconus, conducting clinical research, mechanistic exploration, and translational applications centered on corneal cross-linking technology.
Starting from clinical issues, the team has been continuously advancing research in areas such as transepithelial corneal cross-linking, accelerated corneal cross-linking, oxygen supply to the corneal stroma, and regionally targeted corneal reinforcement, aiming to explore more precise treatment strategies for corneal strengthening.Relevant findings have been published in multiplepieceInternationalSCIacademic journals, resulting in multiple patents and commercialized outcomes.
Patients with keratoconus often face vision loss, progression of refractive errors, and the risk of corneal transplantation. The team has conducted systematic research focused on enhancing the efficacy of corneal cross-linking and developing personalized treatment pathways, providing significant clinical and scientific support for optimizing therapeutic approaches to corneal diseases, and alsoHighlightThe Leading Role of the Ophthalmology Clinical Team in the Translation of Medical-Engineering Interdisciplinary Research
Reason for Award:
Huaxia Eye Hospital Group Co., Ltd. has developed and implemented the “Myopia Prevention and Control Campus Screening System 3.0” tailored to scenarios for myopia prevention and control among children and adolescents, driving the upgrade of campus screening from manual recording and fragmented management to a digital, standardized, and collaborative model.
The system supports QR code scanning, direct hardware connectivity, and real-time data upload, enhancing the efficiency of school-based screenings. It assists medical personnel in screening management through intelligent myopia grading, multi-dimensional visual reports, and abnormal data detection.The system also integrates the home-school service link, allowing parents to view vision reports and trends through Huaxia Smart Hospital.Mini ProgramAccess report interpretation, online consultation, follow-up, and referral services.
Since its launch in 2026, the system has been deployed in numerous hospitals and schools, facilitating large-scale screenings. Its value lies in integrating specialized ophthalmic expertise, digital systems, and campus public health scenarios, thereby providing a replicable service model for the prevention and control of myopia among children and adolescents.
Reason for Award:
Under the leadership of Director Zhou Dan, the Ophthalmology Center of the First Dongguan Hospital Affiliated to Guangdong Medical University has continuously advanced the clinical application of new ophthalmic technologies in the region in recent years, covering multiple areas including complex cataract surgery, minimally invasive glaucoma treatment, and vitreoretinal surgery.
The team has enhanced the regional capacity for diagnosing and treating complex ocular diseases by implementing advanced techniques such as micropulse laser therapy, refractive cataract surgery, and complex vitreoretinal procedures.Meanwhile, the hospital has established the “Glaucoma Home” to create a closed-loop service system encompassing full-cycle diagnosis and treatment, follow-up management, and health education for patients. It also actively participates in public welfare and public health initiatives, including the “Bright Journey” aid program in Tibet, myopia prevention and control, and neonatal fundus screening.
The award was granted for integrating new ophthalmic technologies, chronic disease management, and the development of regional medical service capabilities, thereby facilitating the implementation of more ophthalmic diagnosis and treatment programs at primary care and regional centers, and providing patients with more continuous and accessible ophthalmic medical services.
Conclusion
From functional intraocular lenses and visual brain-computer interfaces, to corneal confocal microscopy, ophthalmic OCT AI, and digital systems for myopia prevention and control, as well as femtosecond lasers, red-light myopia intervention, and innovations in regional eye care services, the award-winning enterprises and institutions at this event cover multiple key directions in ophthalmic technological innovation.
Among them, the Ophthalmic Innovative Device Award highlights the new progress of domestically produced ophthalmic products in terms of national approval for innovative medical devices, advancement through innovation channels, and translation of cutting-edge technologies; while the Ophthalmic Application Innovation Award showcases the practical value of ophthalmic technologies in real-world clinical practice, public health, screening management, and digital services.
The significance of technological innovation in ophthalmic healthcare is ultimately reflected in more precise diagnosis, safer treatment, more continuous management, and broader accessibility.In the future, Siyu MedTech and Eye Future will continue to focus on outstanding enterprises, institutions, and teams in the ophthalmology field that possess clinical value, technological sophistication, and industrialization potential, jointly witnessing the sustained growth of China’s innovative forces in ophthalmology.
